InflaRx (IFRX) Return on Capital Employed (2017 - 2026)
InflaRx (IFRX) posted Return on Capital Employed of 14.9% for Q1 2026, up 349.88% sequentially from 3.31% in Q4 2025, and up 1623.0% YoY from 0.86% in Q1 2025.
InflaRx (IFRX) Return on Capital Employed (2017 - 2026) Analysis & Trends
InflaRx has reported Return on Capital Employed for 10 years, with the latest figure at 14.9% in Q1 2026.
- Quarterly Return on Capital Employed rose 1623.0% year-over-year to 14.9% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 14.9% (up 1623.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
- Return on Capital Employed grew to 14.9% in Q1 2026 per IFRX's latest filing, from 3.31% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 14.9% in Q1 2026 and troughed at 78.01% in Q3 2024.
- A 5-year average of 24.97% and a median of 24.64% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed soared 569406982 bps in 2022, then sank 5460 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 36.18% in 2022, then advanced by 12 bps to 31.78% in 2023, then jumped by 96 bps to 1.16% in 2024, then soared by 385 bps to 3.31% in 2025, then surged by 350 bps to 14.9% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 14.9%, 3.31%, and 11.9% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 7.88% |
| 10 | InflaRx | 142.31 Mn | -41.94 Mn | 2.74 Bn | 13.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.90% |
| Dec 31, 2025 | 3.31% |
| Sep 30, 2025 | 11.90% |
| Jun 30, 2025 | 1.51% |
| Mar 31, 2025 | -1.32% |
| Dec 31, 2024 | -1.16% |
| Sep 30, 2024 | -78.01% |
| Jun 30, 2024 | -58.21% |
| Mar 31, 2024 | -46.03% |
| Dec 31, 2023 | -31.78% |
| Sep 30, 2023 | -23.41% |
| Jun 30, 2023 | -24.64% |
| Mar 31, 2023 | -19.37% |
| Dec 31, 2022 | -36.18% |
| Sep 30, 2022 | -38.83% |
| Jun 30, 2022 | -41.97% |
| Mar 31, 2022 | -55.18% |
| Dec 31, 2021 | -44.52% |
| Sep 30, 2021 | -7.51% |
| Jun 30, 2021 | -4,741,045.81% |